Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Kura Oncology, Inc.
Taiho Oncology, Inc.
Kura Oncology, Inc.
The Methodist Hospital Research Institute
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Celgene
Dana-Farber Cancer Institute
University of Colorado, Denver
Servier
Incyte Corporation
Molecular Partners AG
Bristol-Myers Squibb
The First Affiliated Hospital of Xiamen University
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
Celgene
Novartis
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
PETHEMA Foundation
Pfizer
Medical College of Wisconsin
Celgene
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Incyte Corporation
The First Affiliated Hospital of Soochow University
Maxinovel Pty., Ltd.
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
Celgene
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Colorado, Denver
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Medical University of South Carolina
Stanford University
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Calithera Biosciences, Inc